Your browser doesn't support javascript.
Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.
Zitvogel, Laurence; Derosa, Lisa; Kroemer, Guido.
  • Zitvogel L; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Derosa L; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Kroemer G; Institut National de la Santé Et de la Recherche Medicale (INSERM) U1015, Équipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.
Blood Cancer Discov ; 4(3): 172-175, 2023 05 01.
Article in English | MEDLINE | ID: covidwho-2306644
ABSTRACT

SUMMARY:

In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 / Multiple Myeloma Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Blood Cancer Discov Year: 2023 Document Type: Article Affiliation country: 2643-3230.BCD-22-0213

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 / Multiple Myeloma Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Blood Cancer Discov Year: 2023 Document Type: Article Affiliation country: 2643-3230.BCD-22-0213